In Vitro Transcribed mRNA Vaccines with Programmable Stimulation of Innate Immunity

Bioconjugate Chemistry

Volumn 29, Issue 9, 2018, Pages 3072-3083

  Loomis, Kristin H ^a,b   Lindsay, Kevin E ^a   Zurla, Chiara ^a   Bhosle, Sushma M ^a   Vanover, Daryll A ^a   Blanchard, Emmeline L ^a   Kirschman, Jonathan L ^a   Bellamkonda, Ravi V ^a,c   Santangelo, Philip J ^a  

^a Emory University   (United States)

^b JOHNS HOPKINS UNIVERSITY APPLIED PHYSICS LABORATORY   (United States)

^c Duke University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; AUTOMOTIVE INDUSTRY; IMMUNE SYSTEM;

ANTISENSE; DELIVERY VEHICLE; IMMUNE RESPONSE; IMMUNE STIMULATION; IN-VITRO; INNATE IMMUNITY; LARGE-SCALES; PERFORMANCE; PROGRAMMABLE STIMULATION; PROPERTY;

VACCINES;

MESSENGER RNA; MESSENGER RNA VACCINE; NUCLEOTIDE; RNA VACCINE; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; URIDINE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNOSTIMULATION; IN VITRO STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PROTEIN EXPRESSION; TRANSGENE; ANIMAL; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; INTRAMUSCULAR DRUG ADMINISTRATION; RAW 264.7 CELL LINE;

ANIMALS; ANTIBODY FORMATION; IMMUNITY, CELLULAR; IMMUNITY, INNATE; INJECTIONS, INTRAMUSCULAR; MICE; RAW 264.7 CELLS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; VACCINES, SYNTHETIC;

EID: 85052307821     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.8b00443     Document Type: Article

References (62)

1. Sahin, U., Karikó, K., and Türeci, Ö. (2014) MRNA-Based Therapeutics-Developing a New Class of Drugs. Nat. Rev. Drug Discovery 13 (10), 759-780, 10.1038/nrd4278
2. Deering, R. P., Kommareddy, S., Ulmer, J. B., Brito, L. A., and Geall, A. J. (2014) Nucleic Acid Vaccines: Prospects for Non-Viral Delivery of MRNA Vaccines. Expert Opin. Drug Delivery 11 (6), 885-899, 10.1517/17425247.2014.901308
3. Geall, A. J. and Ulmer, J. B. (2015) Introduction to RNA-Based Vaccines and Therapeutics. Expert Rev. Vaccines 14 (2), 151-152, 10.1586/14760584.2015.1001244
4. Geall, A. J., Mandl, C. W., and Ulmer, J. B. (2013) RNA: The New Revolution in Nucleic Acid Vaccines. Semin. Immunol. 25 (2), 152-159, 10.1016/j.smim.2013.05.001
5. Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L. et al. (2012) Protective Efficacy of in Vitro Synthesized, Specific MRNA Vaccines against Influenza A Virus Infection. Nat. Biotechnol. 30 (12), 1210-1216, 10.1038/nbt.2436
6. Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R. et al. (2017) Zika Virus Protection by a Single Low-Dose Nucleoside-Modified MRNA Vaccination. Nature 543 (7644), 248-251, 10.1038/nature21428
7. DeFrancesco, L. (2017) The "anti-Hype" Vaccine. Nat. Biotechnol. 35 (3), 193-197, 10.1038/nbt.3812
8. Alexopoulou, L., Czopik Holt, A., Medzhitov, R., and Flavell, R. (2001) Recognition of Double-Stranded RNA and Activation of NF-B by Toll-like Receptor 3. Nature 413, 732-738, 10.1038/35099560
9. Karikó, K., Ni, H., Capodici, J., Lamphier, M., and Weissman, D. (2004) MRNA Is an Endogenous Ligand for Toll-like Receptor 3. J. Biol. Chem. 279 (13), 12542-12550, 10.1074/jbc.M310175200
10. Yoneyama, M. and Fujita, T. (2010) Rev. Med. Virol. 20, 4, 10.1002/rmv.633
11. Kindt, T. J., Goldsby, R. A., Osborne, B. A., and Kuby, J. Kuby Immunology; Macmillan, 2007.
12. Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G. et al. (2013) Type I IFN Counteracts the Induction of Antigen-Specific Immune Responses by Lipid-Based Delivery of MRNA Vaccines. Mol. Ther. 21 (1), 251-259, 10.1038/mt.2012.202
13. De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V. K., Smet, M., Sanders, N., Lienenklaus, S. et al. (2016) Type I Interferons Interfere with the Capacity of MRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses. Mol. Ther. 24 (11), 2012-2020, 10.1038/mt.2016.161
14. Devoldere, J., Dewitte, H., De Smedt, S. C., and Remaut, K. (2016) Evading Innate Immunity in Nonviral MRNA Delivery: Don?T Shoot the Messenger. Drug Discovery Today 21 (1), 11-25, 10.1016/j.drudis.2015.07.009
15. Kirschman, J. L., Bhosle, S., Vanover, D., Blanchard, E. L., Loomis, K. H., Zurla, C., Murray, K., Lam, B. C., and Santangelo, P. J. (2017) Characterizing Exogenous MRNA Delivery, Trafficking, Cytoplasmic Release and RNA-Protein Correlations at the Level of Single Cells. Nucleic Acids Res. 45 (12), e113, 10.1093/nar/gkx290
16. Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., and Karikó, K. (2010) Incorporation of Pseudouridine into MRNA Enhances Translation by Diminishing PKR Activation. Nucleic Acids Res. 38 (17), 5884-5892, 10.1093/nar/gkq347
17. Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., and Weissman, D. (2008) Incorporation of Pseudouridine into MRNA Yields Superior Nonimmunogenic Vector with Increased Translational Capacity and Biological Stability. Mol. Ther. 16 (11), 1833-1840, 10.1038/mt.2008.200
18. Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., and Kitada, T. (2015) N1-Methylpseudouridine-Incorporated MRNA Outperforms Pseudouridine-Incorporated MRNA by Providing Enhanced Protein Expression and Reduced Immunogenicity in Mammalian Cell Lines and Mice. J. Controlled Release 217, 337-344, 10.1016/j.jconrel.2015.08.051
19. Svitkin, Y. V., Cheng, Y. M., Chakraborty, T., Presnyak, V., John, M., and Sonenberg, N. (2017) N1-Methyl-Pseudouridine in MRNA Enhances Translation through EIF2α-Dependent and Independent Mechanisms by Increasing Ribosome Density. Nucleic Acids Res. 45 (10), 6023-6036, 10.1093/nar/gkx135
20. Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., and Dewitte, H. (2017) Co-Delivery of Nucleoside-Modified MRNA and TLR Agonists for Cancer Immunotherapy: Restoring the Immunogenicity of Immunosilent MRNA. J. Controlled Release 266, 287-300, 10.1016/j.jconrel.2017.09.041
21. Reed, S. G., Orr, M. T., and Fox, C. B. (2013) Key Roles of Adjuvants in Modern Vaccines. Nat. Med. 19 (12), 1597-1608, 10.1038/nm.3409
22. Fotin-Mleczek, M., Duchardt, K. M., Lorenz, C., Pfeiffer, R., Ojkić-Zrna, S., Probst, J., and Kallen, K.-J. (2011) Messenger RNA-Based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity. J. Immunother. 34 (1), 1-15, 10.1097/CJI.0b013e3181f7dbe8
23. Scheel, B., Teufel, R., Probst, J., Carralot, J.-P., Geginat, J., Radsak, M., Jarrossay, D., Wagner, H., Jung, G., Rammensee, H.-G. et al. (2005) Toll-like Receptor-Dependent Activation of Several Human Blood Cell Types by Protamine-Condensed MRNA. Eur. J. Immunol. 35 (5), 1557-1566, 10.1002/eji.200425656
24. Santangelo, P. J., Lifland, A. W., Curt, P., Sasaki, Y., Bassell, G. J., Lindquist, M. E., and Crowe, J. E. (2009) Single Molecule-Sensitive Probes for Imaging RNA in Live Cells. Nat. Methods 6 (5), 347-349, 10.1038/nmeth.1316
25. Lifland, A. W., Zurla, C., and Santangelo, P. J. (2010) Single Molecule Sensitive Multivalent Polyethylene Glycol Probes for RNA Imaging. Bioconjugate Chem. 21 (3), 483-488, 10.1021/bc9003876
26. Lifland, A. W., Zurla, C., Yu, J., and Santangelo, P. J. (2011) Dynamics of Native β-Actin MRNA Transport in the Cytoplasm. Traffic 12 (8), 1000-1011, 10.1111/j.1600-0854.2011.01209.x
27. Alonas, E., Lifland, A. W., Gudheti, M., Vanover, D., Jung, J., Zurla, C., Kirschman, J., Fiore, V. F., Douglas, A., Barker, T. H. et al. (2014) Combining Single RNA Sensitive Probes with Subdiffraction-Limited and Live-Cell Imaging Enables the Characterization of Virus Dynamics in Cells. ACS Nano 8 (1), 302-315, 10.1021/nn405998v
28. Jung, J., Lifland, A. W., Alonas, E. J., Zurla, C., and Santangelo, P. J. (2013) Characterization of MRNA-Cytoskeleton Interactions In Situ Using FMTRIP and Proximity Ligation. PLoS One 8 (9), e74598, 10.1371/journal.pone.0074598
29. Jung, J., Lifland, A. W., Zurla, C., Alonas, E. J., and Santangelo, P. J. (2013) Quantifying RNA-Protein Interactions in Situ Using Modified-MTRIPs and Proximity Ligation. Nucleic Acids Res. 41 (1), e12, 10.1093/nar/gks837
30. Zurla, C., Lifland, A. W., and Santangelo, P. J. (2011) Characterizing MRNA Interactions with RNA Granules during Translation Initiation Inhibition. PLoS One 6 (5), e19727, 10.1371/journal.pone.0019727
31. Lifland, A. W., Zurla, C., Smith, D. V., Vanover, D., Blanchard, E. L., Alonas, E., Kirschman, J. L., and Santangelo, P. J. (2017) RSV Glycoprotein and Genomic RNA Dynamics Reveal Filament Assembly Prior to the Plasma Membrane. Nat. Commun. 8 (1), 667, 10.1038/s41467-017-00732-z
32. Loomis, K. H., Kirschman, J. L., Bhosle, S., Bellamkonda, R. V., and Santangelo, P. J. (2016) Strategies for Modulating Innate Immune Activation and Protein Production of in Vitro Transcribed MRNAs. J. Mater. Chem. B 4 (9), 1619-1632, 10.1039/C5TB01753J
33. Groves, B., Chen, Y.-J., Zurla, C., Pochekailov, S., Kirschman, J. L., Santangelo, P. J., and Seelig, G. (2016) Computing in Mammalian Cells with Nucleic Acid Strand Exchange. Nat. Nanotechnol. 11 (3), 287-294, 10.1038/nnano.2015.278
34. Uchida, S., Yoshinaga, N., Yanagihara, K., Yuba, E., Kataoka, K., and Itaka, K. (2018) Designing Immunostimulatory Double Stranded Messenger RNA with Maintained Translational Activity through Hybridization with Poly A Sequences for Effective Vaccination. Biomaterials 150, 162-170, 10.1016/j.biomaterials.2017.09.033
35. Sioud, M. (2006) Single-Stranded Small Interfering RNA Are More Immunostimulatory than Their Double-Stranded Counterparts: A Central Role for 2′-Hydroxyl Uridines in Immune Responses. Eur. J. Immunol. 36 (5), 1222-1230, 10.1002/eji.200535708
36. Judge, A., Polisky, B., Vargeese, C., Shaffer, C. S., Morrissey, D. V., MacLachlan, I., Lockridge, J. A., Blanchard, K., Bowman, K., Hartsough, K. et al. (2005) Potent and Persistent in Vivo Anti-HBV Activity of Chemically Modified SiRNAs. Nat. Biotechnol. 23 (8), 1002, 10.1038/nbt1122
37. Halliday, A., Turner, J. D., Guimarães, A., Bates, P. A., and Taylor, M. J. (2016) The TLR2/6 Ligand PAM2CSK4 Is a Th2 Polarizing Adjuvant in Leishmania Major and Brugia Malayi Murine Vaccine Models. Parasites Vectors 9, 96, 10.1186/s13071-016-1381-0
38. Cottalorda, A., Verschelde, C., Marçais, A., Tomkowiak, M., Musette, P., Uematsu, S., Akira, S., Marvel, J., and Bonnefoy-Berard, N. (2006) TLR2 Engagement on CD8 T Cells Lowers the Threshold for Optimal Antigen-Induced T Cell Activation. Eur. J. Immunol. 36 (7), 1684-1693, 10.1002/eji.200636181
39. Geng, D., Zheng, L., Srivastava, R., Velasco-Gonzalez, C., Riker, A., Markovic, S. N., and Davila, E. (2010) Amplifying TLR-MyD88 Signals within Tumor-Specific T Cells Enhances Antitumor Activity to Suboptimal Levels of Weakly Immunogenic Tumor Antigens. Cancer Res. 70 (19), 7442-7454, 10.1158/0008-5472.CAN-10-0247
40. Mercier, B. C., Cottalorda, A., Coupet, C.-A., Marvel, J., and Bonnefoy-Bérard, N. (2009) TLR2 Engagement on CD8 T Cells Enables Generation of Functional Memory Cells in Response to a Suboptimal TCR Signal. J. Immunol. 182 (4), 1860-1867, 10.4049/jimmunol.0801167
41. Yang, Q., Wang, B., Yu, H., Zhu, Y., Wang, X., Jiang, H., Wang, C., Peng, J., and Hou, M. (2011) TLR7 Promotes Th1 Polarization in Immune Thrombocytopenia. Thromb. Res. 128 (3), 237-242, 10.1016/j.thromres.2011.02.024
42. Misiak, A., Leuzzi, R., Allen, A. C., Galletti, B., Baudner, B. C., D'Oro, U., O'Hagan, D. T., Pizza, M., Seubert, A., and Mills, K. H. G. (2017) Addition of a TLR7 Agonist to an Acellular Pertussis Vaccine Enhances Th1 and Th17 Responses and Protective Immunity in a Mouse Model. Vaccine 35 (39), 5256-5263, 10.1016/j.vaccine.2017.08.009
43. Hung, I. F. N., Zhang, A. J., To, K. K. W., Chan, J. F. W., Li, C., Zhu, H.-S., Li, P., Li, C., Chan, T.-C., Cheng, V. C. C. et al. (2014) Immunogenicity of Intradermal Trivalent Influenza Vaccine with Topical Imiquimod: A Double Blind Randomized Controlled Trial. Clin. Infect. Dis. 59 (9), 1246-1255, 10.1093/cid/ciu582
44. Van Hoeven, N., Fox, C. B., Granger, B., Evers, T., Joshi, S. W., Nana, G. I., Evans, S. C., Lin, S., Liang, H., Liang, L. et al. (2017) A Formulated TLR7/8 Agonist Is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines. Sci. Rep. 7, 46426, 10.1038/srep46426
45. Bagnoli, F., Fontana, M. R., Soldaini, E., Mishra, R. P. N., Fiaschi, L., Cartocci, E., Nardi-Dei, V., Ruggiero, P., Nosari, S., De Falco, M. G. et al. (2015) Vaccine Composition Formulated with a Novel TLR7-Dependent Adjuvant Induces High and Broad Protection against Staphylococcus Aureus. Proc. Natl. Acad. Sci. U. S. A. 112 (12), 3680-3685, 10.1073/pnas.1424924112
46. Wille-Reece, U., Flynn, B. J., Loré, K., Koup, R. A., Kedl, R. M., Mattapallil, J. J., Weiss, W. R., Roederer, M., and Seder, R. A. (2005) HIV Gag Protein Conjugated to a Toll-like Receptor 7/8 Agonist Improves the Magnitude and Quality of Th1 and CD8+ T Cell Responses in Nonhuman Primates. Proc. Natl. Acad. Sci. U. S. A. 102 (42), 15190-15194, 10.1073/pnas.0507484102
47. Moyer, T. J., Zmolek, A. C., and Irvine, D. J. (2016) Beyond Antigens and Adjuvants: Formulating Future Vaccines. J. Clin. Invest. 126 (3), 799-808, 10.1172/JCI81083
48. Kariko, K., Muramatsu, H., Ludwig, J., and Weissman, D. (2011) Generating the Optimal MRNA for Therapy: HPLC Purification Eliminates Immune Activation and Improves Translation of Nucleoside-Modified, Protein-Encoding MRNA. Nucleic Acids Res. 39 (21), e142-e142, 10.1093/nar/gkr695
49. Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P., Smith, Z. D., Meissner, A. et al. (2010) Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells Using Synthetic Modified MRNA. Cell Stem Cell 7 (5), 618-630, 10.1016/j.stem.2010.08.012
50. Uchida, S., Kataoka, K., and Itaka, K. (2015) Screening of MRNA Chemical Modification to Maximize Protein Expression with Reduced Immunogenicity. Pharmaceutics 7 (3), 137-151, 10.3390/pharmaceutics7030137
51. Schett, G., Dayer, J.-M., and Manger, B. (2016) Interleukin-1 Function and Role in Rheumatic Disease. Nat. Rev. Rheumatol. 12 (1), 14-24, 10.1038/nrrheum.2016.166
52. Söderberg, O., Leuchowius, K.-J., Gullberg, M., Jarvius, M., Weibrecht, I., Larsson, L.-G., and Landegren, U. (2008) Characterizing Proteins and Their Interactions in Cells and Tissues Using the in Situ Proximity Ligation Assay. Methods 45 (3), 227-232, 10.1016/j.ymeth.2008.06.014
53. Berghaus, L. J., Moore, J. N., Hurley, D. J., Vandenplas, M. L., Fortes, B. P., Wolfert, M. A., and Boons, G.-J. (2010) Innate Immune Responses of Primary Murine Macrophage-Lineage Cells and RAW 264.7 Cells to Ligands of Toll-like Receptors 2, 3, and 4. Comp. Immunol. Microbiol. Infect. Dis. 33 (5), 443-454, 10.1016/j.cimid.2009.07.001
54. Takakura, Y., Atsumi, R., Hashida, M., and Sezaki, H. (1987) Development of a Novel Polymeric Prodrug of Mitomycin C, Mitomycin C-Dextran Conjugate with Anionic Charge. II. Disposition and Pharmacokinetics Following Intravenous and Intramuscular Administration. Int. J. Pharm. 37 (1), 145-154, 10.1016/0378-5173(87)90019-6
55. Jewell, C. M., Bustamante López, S. C., and Irvine, D. J. (2011) In Situ Engineering of the Lymph Node Microenvironment via Intranodal Injection of Adjuvant-Releasing Polymer Particles. Proc. Natl. Acad. Sci. U. S. A. 108 (38), 15745-15750, 10.1073/pnas.1105200108
56. Bhosle, S. M., Loomis, K. H., Kirschman, J. L., Blanchard, E. L., Vanover, D. A., Zurla, C., Habrant, D., Edwards, D., Baumhof, P., Pitard, B. et al. (2018) Unifying in Vitro and in Vivo IVT MRNA Expression Discrepancies in Skeletal Muscle via Mechanotransduction. Biomaterials 159, 189-203, 10.1016/j.biomaterials.2018.01.010
57. Kanneganti, T.-D., Body-Malapel, M., Amer, A., Park, J.-H., Whitfield, J., Franchi, L., Taraporewala, Z. F., Miller, D., Patton, J. T., Inohara, N. et al. (2006) Critical Role for Cryopyrin/Nalp3 in Activation of Caspase-1 in Response to Viral Infection and Double-Stranded RNA. J. Biol. Chem. 281 (48), 36560-36568, 10.1074/jbc.M607594200
58. Smirnov, D., Schmidt, J. J., Capecchi, J. T., and Wightman, P. D. (2011) Vaccine Adjuvant Activity of 3M-052: An Imidazoquinoline Designed for Local Activity without Systemic Cytokine Induction. Vaccine 29 (33), 5434-5442, 10.1016/j.vaccine.2011.05.061
59. Schlake, T., Thess, A., Fotin-Mleczek, M., and Kallen, K.-J. (2012) Developing MRNA-Vaccine Technologies. RNA Biol. 9 (11), 1319-1330, 10.4161/rna.22269
60. Kumar, S., Anselmo, A. C., Banerjee, A., Zakrewsky, M., and Mitragotri, S. (2015) Shape and Size-Dependent Immune Response to Antigen-Carrying Nanoparticles. J. Controlled Release 220, 141-148, 10.1016/j.jconrel.2015.09.069
61. Toy, R. and Roy, K. (2016) Engineering Nanoparticles to Overcome Barriers to Immunotherapy. Bioeng. Transl. Med. 1 (1), 47-62, 10.1002/btm2.10005
62. Pulendran, B. and Ahmed, R. (2011) Immunological Mechanisms of Vaccination. Nat. Immunol. 12, 509-517, 10.1038/ni.2039